Testicular Cancer: A Urologic Oncology Approach
Testicular cancer, while rare, is the most common cancer in young men aged 15-35. From a urologic oncology perspective, testicular cancer is notable for its excellent prognosis and remarkable responsiveness to multimodal therapy. Even advanced metastatic disease has exceptional cure rates exceeding 95 percent when treated appropriately. Dr. Libby brings urologic oncology expertise to testicular cancer management, ensuring coordinated surgical and systemic therapy for optimal outcomes.
Surgical Management: Radical Inguinal Orchiectomy
Surgical removal of the affected testicle through an inguinal approach is both diagnostic and therapeutic. Dr. Libby performs this procedure with attention to oncologic principles, including avoidance of scrotal incisions that could compromise lymphatic drainage, appropriate removal of surrounding tissue, and high ligation of the spermatic cord. This approach prevents tumor spillage and allows comprehensive pathologic staging. The procedure is minimally morbid, with most men returning to normal activities within one to two weeks.
Staging and Risk Stratification
Accurate staging is essential for testicular cancer management. Staging combines clinical assessment (physical exam and imaging) with prognostic tumor markers (AFP, beta-hCG, LDH). Patients are stratified into good-risk, intermediate-risk, and poor-risk categories based on tumor markers, histology, and radiographic findings. This stratification guides recommendations for observation versus chemotherapy in early-stage disease and predicts response to treatment in advanced disease.
Early-Stage Disease Management
Stage IA and IB (No Residual Masses)
Following orchiectomy, men with early-stage disease and normal tumor markers have several management options. Active surveillance involves regular clinical examination, imaging, and tumor marker monitoring to detect recurrence promptly. Alternatively, single-agent chemotherapy (carboplatin) or multiagent chemotherapy reduces relapse risk for intermediate-risk patients. Dr. Libby discusses these options with each patient, considering histologic features and individual preferences.
Residual Masses After Chemotherapy
When residual abdominal masses persist after chemotherapy, surgical resection via retroperitoneal lymph node dissection (RPLND) may be necessary. This is a complex procedure requiring urologic oncology expertise. It's performed when imaging shows mature teratoma, necrosis, or fibrosis that won't resolve with further chemotherapy.
Advanced Disease and Chemotherapy
For patients with advanced metastatic disease, chemotherapy is highly effective. Standard regimens include BEP (bleomycin, etoposide, cisplatin) and EP (etoposide, cisplatin), administered in multiple cycles. Dr. Libby works closely with medical oncology colleagues to coordinate care, manage side effects, and provide comprehensive support during treatment. Even patients with poor-risk disease achieve 70-90 percent cure rates with appropriate chemotherapy.
Fertility and Sexual Function Considerations
Testicular cancer and its treatment can impact fertility and sexual function. Baseline semen analysis and sperm banking before surgery or chemotherapy should be discussed with men concerned about future paternity. Most men retain sexual function after orchiectomy, and hormone replacement is typically not necessary. Dr. Libby addresses these quality-of-life issues comprehensively and provides referrals to reproductive specialists when appropriate.
Salvage Therapy for Recurrent Disease
Occasionally, testicular cancer recurs after initial chemotherapy. Salvage chemotherapy with more intensive regimens or high-dose chemotherapy with stem cell rescue may be offered. Dr. Libby works with medical oncology colleagues to explore all therapeutic options for recurrent disease.
Long-Term Follow-Up and Survivorship
Testicular cancer survivors require long-term monitoring for late effects of treatment, including second malignancies, cardiac toxicity, and pulmonary toxicity. Dr. Libby provides survivorship care and coordinates with oncologists to monitor for late complications. Most testicular cancer survivors achieve excellent long-term quality of life and return to normal function.
Multidisciplinary Testicular Cancer Care
Optimal testicular cancer treatment requires coordination among urologic surgeons, medical oncologists, radiation oncologists, and other specialists. Dr. Libby serves as the lead urologic specialist, coordinating surgical timing, assessing residual masses, and providing comprehensive counseling. Patients benefit from a team approach ensuring all treatment modalities are optimized for their specific situation.
When to Refer for Urologic Oncology Care
Patients with newly diagnosed testicular cancer, those with residual masses after chemotherapy, or those experiencing recurrence benefit from urologic oncology consultation. If your primary care physician or another specialist has recommended testicular cancer evaluation, Dr. Libby provides comprehensive assessment and coordinates multidisciplinary treatment.